secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001628280-23-000551
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter plans spinoff of Renal Care & Acute Therapies into public company; COO resigns
--------------------------------------------------------------------------------

- Spinoff of Renal Care and Acute Therapies into independent public company expected in 12-18 months; 2021 sales of those businesses ~$5B.
- Exploring strategic alternatives for BioPharma Solutions (BPS), including a potential sale or other separation.
- Simplifying operating model and manufacturing footprint; restructuring details to be provided on Feb 9, 2023 earnings call.
- COO Giuseppe Accogli resigned effective January 4, 2023; no longer an executive officer.
- New kidney care company would address ~$15B market with estimated 3-4% CAGR over next three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023000551/0001628280-23-000551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023000551/bax-20230104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer